MDLNMedline Inc.

Healthcare

$36.26

$31.6152 weeks$49.99

Is it safe?

Mixed

Forensics clean, with a caveat: a safe balance sheet and clean books, but big price swings.

2 good, 1 to watch, 2 neutral, 1 without data

SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Insider conviction-$879.9M

Insiders were net sellers (-$879.9M, 90 days to Oct 8, 2026), selling is often routine.

Credit gradeBBBderived · Jun 27, 2026

Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.

Drawdown risk46% volderived · Oct 9, 2026

Large price swings, high volatility. Worst drawdown -37% · now 27% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitymiddle of the market

Max drawdowntop 5% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can MDLN take a bad year?

Medline Inc. carries $9.90B of net debt at 3.43× EBITDA: a load its earnings can carry.

$9.90B

Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business

Net debt / EBITDA: 3.43×
Net debt / EBITDA
Altman Z-score: 3.29
Altman Z-score · safe zone, above 3
Interest cover: 2.45×
Interest cover · operating profit covers the interest bill, with room to spare